NovoCure (NASDAQ: NVCR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-07-28 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.180 | -0.040 | 0.1400 | ||||
REV | 134.080M | 137.547M | 3.467M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of NovoCure (NASDAQ: NVCR) through any online brokerage.
Other companies in NovoCure’s space includes: Steris (NYSE:STE), Masimo (NASDAQ:MASI), Envista Holdings (NYSE:NVST), Koninklijke Philips (NYSE:PHG) and Smith & Nephew (NYSE:SNN).
The latest price target for NovoCure (NASDAQ: NVCR) was reported by HC Wainwright & Co. on Monday, May 16, 2022. The analyst firm set a price target for 115.00 expecting NVCR to rise to within 12 months (a possible 56.89% upside). 10 analyst firms have reported ratings in the last year.
The stock price for NovoCure (NASDAQ: NVCR) is $73.3 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for NovoCure.
NovoCure’s Q2 earnings are confirmed for Thursday, July 28, 2022.
There is no upcoming split for NovoCure.
NovoCure is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.